2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on SCLC: Anti-PD-1/L1 Staple for 1st L Treatment (Atezolizumab and Durvalumab + EP Improve OS, Pembro Improve PFS) & Safety, Tolerability and Efficacy of Liposomal Irinotecan in 2nd L Setting
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Jason Porter
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Jason Porter
Login to view comments.
Click here to Login
